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Abstract
NOD mice exhibit major defects in the earliest stages of T cell development in the thymus.
Genome-wide genetic and transcriptome analyses were used to investigate the origins and
consequences of an early T cell developmental checkpoint breakthrough in Rag1-deficient NOD
mice. QTL analysis mapped the presence of checkpoint breakthrough cells to several known NOD
diabetes susceptibility regions, particularly Idd9/11 on chromosome 4, suggesting common
genetic origins for T cell defects affecting this trait and autoimmunity. Genome-wide RNA deep-
sequencing of NOD and B6 Rag1-deficient thymocytes revealed the effects of genetic background
prior to breakthrough, as well as the cellular consequences of the breakthrough. Transcriptome
comparison between the two strains showed enrichment in differentially expressed signal
transduction genes, prominently tyrosine kinase and actin-binding genes, in accord with their
divergent sensitivities to activating signals. Emerging NOD breakthrough cells aberrantly
expressed both stem cell-associated proto-oncogenes, such as Lmo2, Hhex, Lyl1, and Kit which
are normally repressed at the commitment checkpoint, and post-β-selection checkpoint genes
including Cd2 and Cd5. Co-expression of genes characteristic of multi-potent progenitors and
more mature T cells persists in the expanding population of thymocytes, and in the thymic
leukemias that emerge with age in these mice. These results show that Rag1-deficient NOD
thymocytes have T cell defects that can collapse regulatory boundaries at two early T cell
checkpoints, which may predispose them to both leukemia and autoimmunity.
Introduction
All T cells arise from a small pool of multipotent progenitors, which undergo proliferation
and tightly controlled developmental programming induced and sustained by interactions
with the thymic environment rich in Notch ligands and cytokines (1, 2). Thymic precursors
are CD4 and CD8 double negative (DN)2, and are defined by sequential changes in surface
Kit (CD117), CD25, and CD44 into stages: DN1 (or early T cell progenitor, ETP;
KithiCD44hiCD25−), DN2 (KithiCD44hiCD25+), DN3 (KitloCD44loCD25+), and DN4
(KitloCD44loCD25lo) (3, 4). A TCR-independent commitment checkpoint has recently been
identified within the DN2 stage, marked by decreased Kit expression from the multipotent
DN2a stage to the committed DN2b stage (5), and dependent on Bcl11b (6, 7). DN2a cells,
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like more immature DN1/ETP cells, undergo proliferative expansion and express legacy
stem/progenitor genes such as Kit, Lyl1, Tal1, Gfi1b, and Sfpi1 (PU.1). These features
decline sharply in the DN2b/DN3 stages when T cell specification genes are strongly
activated, proliferation slows, and efficient TCR gene rearrangement begins (5, 8). Thus, the
T cell commitment checkpoint divides the TCR-negative stages of development into two
phases: Phase I, wherein cells proliferate and retain alternative lineage potential, and Phase
II, which prepares committed DN3 cells for the first TCR-dependent checkpoint, β-selection
(9). Normally, only cells that successfully rearrange a TCRβ and assemble a signaling pre-
TCR complex are permitted to pass through the β-selection checkpoint to DN4 and
proliferate. These cells then become CD4+CD8+ double positive (DP), express TCRαβ, and
undergo positive and negative selection (10, 11). Rag-deficient T cells are blocked at β-
selection and do not generate DP cells.
The non-obese diabetic (NOD) mouse is a model of T cell mediated autoimmune Type 1
diabetes, with over 20 genetic regions associated with diabetes susceptibility, many of which
specifically affect T cell activities (12–15). Most T lineages have been implicated in
autoimmune susceptibility or resistance in NOD mice, including CD4, CD8, NKT, Treg, and
γδT cells (16), raising the possibility that all NOD T cells may share fundamental
abnormalities that contribute to loss of self-tolerance and might be traceable to their
common progenitors (8). We previously reported defects in the earliest stages of T cell
development in both wild type (WT) and TCR-deficient NODmice. Precursor cells from WT
NOD mice exhibit impairedαβT-cell development and enhanced γδT-cell generation
apparently arising from the ETP-DN2 stages (17). In addition, the NOD genetic background
severely compromises β-selection checkpoint control: despite the absence of TCRexpression
in NOD.SCID and NOD.Rag1−/− (NOD.Rag) mice, aberrant breakthrough DP thymocytes
spontaneously appear in all young adult animals (18). These TCR-negative DP cells do not
fully mimic normal β-selected cells, as they still express receptors characteristic of earlier
DN stages, like Kit, IL7Rα, and CD25, which are normally turned off by the DP stage (18).
Furthermore, older NOD.SCID and NOD.Rag mice develop thymic tumors at high
frequency while mice of other strains with these immunodeficiencies do not (18–21). This
suggests a possible link between early T cell checkpoint control and tumor suppression that
may be jointly defective in the NOD genetic background.
We used genome-wide genetic and transcriptome analytical methods to investigate the
source and consequences of the NOD.Rag thymocyte checkpoint defect. First, we found
quantitative trait loci (QTLs) for this trait, all within several of known diabetes susceptibility
regions mapped in WT NOD mice. A major QTL localized within the Idd9/11 region of
chromosome (chr)4 was confirmed using congenic mice. In addition, genome-wide
transcriptome analyses revealed distinct differences in gene expression between thymocytes
from NOD.Rag and B6.Rag control mice. The genes differentially expressed between the
two strains were enriched for those encoding signaling proteins, suggesting aberrant signal
transduction as a possible precondition for breakthrough. Furthermore, newly emergent
NOD.Rag breakthrough cells fail to terminate gene expression programs from earlier stages:
they co-express Phase I stem/progenitor genes along with T cell-specific genes characteristic
of Phase II and post-β-selection stages. This mixed gene expression profile foreshadows the
phenotype of thymic tumors found in older mice of this strain, which share characteristics
with classes of human early-type acute T cell lymphoblastic leukemia (T-ALL), suggesting
that primary defects in early T cell checkpoint control underlie some forms of T-ALL.
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Materials and Methods
Mice and crosses
B6.129S7-Rag1tm1Mom/J (B6.Rag) and NOD.Cg-Rag1tm1Mom Prf1tm1Sdz/SzJ (NOD.Rag)
(The Jackson Laboratory) and NOD.B10Idd9 Line 905 (14) (Taconic Farms) mice were bred
and maintained in the Caltech Laboratory Animal Facility using autoclaved cages, food, and
water. All animal protocols were reviewed and approved by the Animal Care and Use
Committee of the California Institute of Technology.
Genetic crosses, QTL analysis, and congenic mice
For the QTL analysis B6.Rag and NOD.Rag mice were crossed and intercrossed for F2 or
backcrossed to NOD.Rag for N2 progeny. Thymocytes from 12–14 wk progeny were
phenotyped by flow cytometric analysis. DNA was extracted from tail tips of 150 N2 and 30
F2 cross mice and 150 polymorphic SNPs were genotyped by Jackson Laboratories Genetic
Services. QTL analysis was carried out using the R-qtl program (22) and p-values were
obtained from genome-wide significance test using 5,000 permutations (23). Congenic
NOD.B10Idd9 Rag mice were created by crossing NOD.Rag and NOD.B10Idd9 mice and
repeated backcrossing until the knockout Rag1 gene and the B10Idd9 region were
homozygous, as determined by PCR analysis.
Cell cultures and antibody staining
Freshly isolated thymocytes were either stained immediately for flow cytometetric analysis
or cultured on OP9-DL1 or -DL4 cells with 5 ng/ml of IL-7, as previously described (17).
For cell stimulations, thymocytes were cultured for 1 h in RPMI supplemented with 10%
fetal bovine serum (Gibco) before treatment with PMA. Cells were immediately fixed in
1.5% formaldehyde in PBS at 37°C and permeabilized by slow addition of ice-cold
methanol to a final concentration of 90%. Cells were incubated on ice for 30 min, washed
with PBS plus 0.5% BSA, and incubated with either phospho-p42/p44 (Erk1/2)-AlexaFluor
647 antibodies or isotype controls (Cell Signaling Technology, Danvers, MA) before
washing and flow cytometric analysis.
Genome-wide transcriptome analysis
CD25+ DN thymocytes were FACS-sorted from NOD.Rag mice at 4 wks of age (pre-
breakthrough) and 7 wks (at the time of first breakthrough), and age-matched B6.Rag mice
for RNA extraction. mRNA purification and cDNA library building were performed as
described (24). Sequencing was done using Illumina High Throughput Genome Analyzer IIx
sequencers at Caltech’s Jacobs Genetics and Genomics Laboratory and the data have been
deposited in NCBI’s Gene Expression Omnibus (25) and are accessible through GEO Series
accession number GSE40688 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE40688). Computational analysis was carried out using software developed at
Caltech (26, 27) as well as Mathematica and R. For analysis, 38 bp, single-read raw
sequence reads were trimmed to 32 bp and mapped onto the mouse genome build NCBI37/
mm9 using Bowtie (bowtie-0.12.1, http://bowtie-bio.sourceforge.net/index.shtml) with
setting ‘-v 2 -k 11 -m 10 -t --best --strata’. The mappable data were then processed by the
ERANGE v. 3.3 RNA-Seq analysis program to obtain the expression level in reads per
kilobase per million reads (RPKM) for each gene (26). We obtained 13–17 × 106 mappable
reads per sample for analysis. Based on a pair-wise comparison between samples, B4 values
were divided by 1.27 to remove a scaling artifact. Genes were required to have at least one
sample with 32 mappable reads (based on a significance level of 0.05, with a Bonferonni
adjustment for 12000 comparisons) and have an annotated transcript name, leaving 11,098
named genes for further analysis. For each gene, comparisons of expression in the four
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samples were calculated as differences on a log2 scale, after replacing any zeros by 0.01 as
an approximate limit of detection. The significance probabilities (p-values) were based on
the assumption of Poisson distributions of counts, under the null hypothesis of equal rates,
allowing for the difference in the number of Mb sequenced (and mapped). Three-fold
change is typically the more stringent requirement and was used to determine the
differentially expressed genes. The statistical significance requirement screens out some
genes with low expression whose 3-fold differences might be attributable to sampling
variation. The design does not permit assessing extra-Poisson variation, which would be
more important at larger expression levels, where the 3-fold criterion rather than the
statistical comparison is the dominant concern.
To profile the connection between different populations, hierarchical clustering was carried
out for each selected subgroup of genes from B6.Rag and NOD.Rag samples or WT B6 ETP
to DP populations (24). Individual mRNA data for the selected genes were first normalized
by the corresponding geometric mean (GeoMean) of comparing populations, then, one-
dimensional hierarchical clustering (along genes) was performed on the results after log2
transformation. Euclidean distance and Ward linkage were used (MATLAB 7.10.0).
Clusters were visualized as heat maps.
Real-time QPCR analysis
QPCR was carried out based on selected RNA-Seq results using FACS-sorted thymocyte
samples. RNA was extracted and reverse-transcribed and QPCRs were carried out using
SyBr GreenER (Invitrogen) in a GeneAmp 7900HT Sequence Detection System (Applied
Biosystems), as previously described (17). Relative expression was calculated for each gene
by the ΔCT (change in cycling threshold) method, normalized toβ-actin expression. Primer
sequences were as previously published (6, 28) plus: Zap70: F-5′-
TGTCCTCCTGAGATGTATGCAC-3′, 5′-ATAGTTCCGCATACGTTGTTCC-3′; Ptcra:
5′-CTGGCTCCACCCATCACACT-3′, R-5′-TGCCATTGCCAGCTGAGA-3′; Notch1:
F-5′-CCACTGTGAACTGCCCTATGT-3′, R-5′-TTGTTTCCTGGACAGTCATCC-3′;
Heyl: F-5′-AAGCTGGAGAAAGCTGAGGTC-3′, R-5′-
CCAATACTCCGGAAGTCAACA-3′; Kit: 5′-ACTTCGCCTGACCAGATTAAA-3′,
R-5′-CGTACGTCAGGATTTCTGGTT-3′; Hhex: F-5′-
ACTACACGCACGCCCTACTC-3′, R-5′-GTCGTTGGAGAACCTCACTTG-3′; Epha2:
F-5′-CAGGAAGGCTACGAGAAGGTC-3′, R-5′-CAGGGTATGCTCTGGACACTC-3′;
Mllt4: F-5′-GACTGGACAGTGACAGGGTGT-3′, R-5′-
CAGTATCAGTTCAGGCCCAGT-3′; Dapk1: F-5′-CATCACCCTGCATGAGGTCTA-3′,
R-5′-TGCCTCCTCTTCAGTCAGAGA-3′; Vegfa: F-5′-
CTCCGAAACCATGAACTTTCT-3′, R-5′-ATGGGACTTCTGCTCTCCTTC-3′; Tnfrsf9:
F-5′-GCTGGCCCTGATCTTCATTA -3′, R-5′-ATCGGCAGCTACAAGCATCT -3′. The
Tcf7 primers (28) yielded lower values than previously published (5), however, the relative
efficiency was consistent between samples in these experiments.
Results
The NOD.Rag breakthrough trait maps to the Idd9/11 region of chr4
We previously reported that aberrant Kit+DP breakthrough cells spontaneously appear in the
thymuses of all male and female NOD.Rag mice by 8 weeks of age, while B6.Rag and (B6
X NOD)F1.Rag thymocytes arrest normally in DN3 at theβ-selection checkpoint (18). To
map the genetic basis of the T cell breakthrough, we tested progeny from a (B6 X
NOD)F2.Rag intercross and an N2 backcross with NOD.Rag as the recurrent parent.
Thymocytes from individual parental and cross progeny were phenotyped by flow cytometry
at 12–14 wks of age for two traits: (1) the percentage of CD4+ (including DP) cells, which is
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indicative of illegitimate progression past theβ-selection checkpoint, and (2) the percentage
of Kit+ cells, indicative of a failure to downregulate a key Phase I stem/progenitor gene (see
Fig. 1E for a model of developmental stages). As shown in Figure 1A, B6.Rag and (B6 X
NOD)F1.Rag mice at 12 wks of age exhibited very few CD4+ or Kit+ cells, whereas the
majority of thymocytes from NOD.Rag mice were CD4+ and Kit+. Results for individual
progeny differed, e.g. #87 exhibited a non-breakthrough phenotype similar to B6.Rag and
#86 showed Kit+CD4+ breakthrough cells like NOD.Rag mice. The F2 intercross yielded a
low percentage of progeny with elevated percentages of CD4+ and/or Kit+ cells (<10%),
whereas approximately 35% of N2 backcross progeny exhibited T cell breakthrough.
Despite indicating differing developmental defects, the traits are not independent, as shown
in the strong correlation (R2=0.82) between the log-transformed percentages of CD4+ and
Kit+ cells for individual progeny (Fig. 1B).
For the QTL analysis, 150 N2 and 30 F2 phenotyped progeny were genotyped for 150
polymorphic SNPs distributed over the 19 autosomal chromosomes. Genome-wide one-
dimensional QTL scans were performed using R-qtl on data from the N2 and F2 crosses
alone and combined (22). Peak QTL LOD scores for the two phenotypes and the N2 and F2
crosses, individually and combined, are shown in Table 1, and genome-wide QTL scans for
the combined cross data are shown in Fig. 1C. A highly significant QTL (LOD >12) was
detected on distal chr4 for both %CD4+ and %Kit+ in both the N2 and the combined cross
(Fig. 1C, D). Weaker QTLs were detected on chr17 for both phenotypes and N2 and
combined crosses (LOD > 3 for %Kit) (Fig. 1C, D), and on chr13, in the N2 cross only
(LOD>2.5). A scan using the F2 cross alone revealed only a suggestive locus on chr11.
Remarkably, all four of these QTLs map to known NOD insulin dependent diabetes
susceptibility (Idd) QTL regions. The chr4 QTL lies within the Idd9/11 region (14, 29, 30),
the chr17 QTL encompasses the region containing Idd1, Idd16, Idd23, and Idd24 (31–33)
(Fig. 1D), the chr13 QTL region overlaps with Idd14 (34), and the chr11 QTL region
overlaps with Idd4 (29). These results allow the possibility that the same genes could be
involved in the loss of checkpoint control and susceptibility to autoimmune diabetes in NOD
mice.
Control of %CD4+ and %Kit+ mapped to the same genetic regions, therefore they arise from
linked or identical genetic sources, and distinct from the Cd4 (chr6) or Kit (chr5) genes
themselves. The aberrant upregulation of CD4 occurs in cells that already express high
levels of Kit (18), and results in Fig. 1B support this: no progeny were %CD4+ high %Kit+
low (right bottom quadrant), whereas a few progeny were %Kit+ high %CD4 low (left top
quadrant). Also, QTL LOD scores for %Kit+ were typically higher than for %CD4 (Table 1,
Fig. 1C, D), indicating that Kit may be a more sensitive measure of breakthrough. These
cells express CD25 and IL7Rα, as well as Kit (18), and their abnormal coexpression with
CD4 (and CD8) suggests that the breakthrough arises from specific genes on the NOD
genetic background that cause bypass of both the T cell commitment and β-selection
checkpoints, as shown in Fig. 1E (and discussed further below).
The congenic B10Idd9 region of chr4 attenuates the NOD.Rag thymocyte breakthrough
To confirm the presence of a gene or genes in the NOD Idd9/11 chr4 QTL region
controlling the breakthrough trait, NOD.B10Idd9 congenic mice (Line 905) (14) were bred to
NOD.Rag to generate a NOD.B10Idd9Rag congenic mouse line. The congenic chr4 region
contains at least three distinct diabetes resistance alleles from B10 mice, Idd9.1, Idd9.2 and
Idd9.3 (Fig. 2A), as well as a possible Idd11 locus (30). The NOD.B10Idd9Rag mice showed
significantly lower percentages of CD4+ and DP breakthrough cells than NOD.Rag mice
(Fig. 2B, C), demonstrating that the chr4 congenic region includes at least one gene involved
in susceptibility to thymocyte breakthrough. Other genetic regions also contribute, as
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NOD.B10Idd9Rag congenic thymocytes exhibited more breakthrough cells than B6.Rag
(Fig. 2B, C), in accord with the QTL analysis.
Differentially expressed genes between Rag-deficient NOD and B6 CD25+DN cells are
enriched for actin-binding and signal transduction genes
Insights into the breakthrough program should emerge from both determining underlying
strain-specific gene expression differences that precede the loss of checkpoint control, and
investigating the earliest post-breakthrough changes. To first evaluate differences between
NOD.Rag and B6.Rag thymocytes that restrict checkpoint control loss to the NOD
background, we carried out a genome-wide RNA deep sequencing analysis (RNA-Seq) (26),
comparing sorted CD4−CD25+DN thymocytes from NOD.Rag mice at 4 wks (N4, before
breakthrough) and 7 wks (N7, early breakthrough), with corresponding non-breakthrough
cells from B6.Rag mice at 4 (B4) and 7 (B7) wks. In each sample, the sorted cells are
predominantly pre-β-selection DN3 cells and they were phenotypically similar (Fig. 3A).
Of >11,000 expressed genes, 412 genes were differentially expressed by at least 3-fold
between the two strains (excluding 10 genes more prominently differing between N7 and
N4, see below) (Fig. 3B, C, and Supplemental Table 1). These genes are normally expressed
in at least one stage of T cell development, from ETP to DP, based on our data from WT B6
mice (24), as shown in heatmaps in Fig. 3D. Genes with strain-specific differences in
expression, at higher and lower levels in NOD cells, exhibit highly varied patterns of
expression across these stages of T-cell development, in contrast to what we find with genes
specific to N7 post-breakthrough cells (see below). Overall, 34% of the strain-dependent
differentially expressed genes have peak expression in Phase I (23% ETP, 11% DN2a), 40%
in Phase II (19% DN2b, 21% DN3), and 26% in post-β-selection DP cells.
Gene ontology analysis of the differentially expressed genes using DAVID Bioinformatics
Resources 6.7 (35) showed three types of genes were overrepresented: MHC (H2),
signaling, and actin-binding protein genes (Table 2). Enrichment of H2 genes is not
unexpected due to their expression diversity between mouse strains, although no role is
known for them in early T cell development. Protein kinase genes, including tyrosine and
serine/threonine kinases, were enriched, as were adherens junction protein genes, which
include actin-binding, tyrosine kinase, and calmodulin-binding protein genes. All of these
protein classes play critical roles in modulating signal transduction activity in T cells (36).
Notably, all 11 of the differentially expressed tyrosine kinases were higher in NOD.Rag
cells, suggesting that the two strains likely exhibit differences in signaling activity. This may
not only contribute to checkpoint failure, but also promote the thymic lymphomas that
develop in these mice, as tyrosine kinases are common oncogenes and therapeutic targets in
leukemia and other malignancies (37).
Several genes differentially expressed between NOD.Rag and B6.Rag are located within and
near the chr4 QTL peak region (Supplemental Table 1). RNA-Seq tracks for several of these
genes are shown in Fig. 3E, including Epha2, an ephrin tyrosine kinase receptor strongly
expressed in both NOD samples; Padi3, a peptidyl arginine deiminase; Tnfrsf9 (CD137,
4-1BB, an Idd9.3 candidate gene (14)); Ctnnbip1 (ICAT), a Wnt pathway inhibitor; and
Hdac1, a histone deacetylase, which is differentially spliced. These genes contrast with the
stably expressed chr4 region gene, Lck. Furthermore, a number of poorly defined
transcription units are differentially expressed between the two strains, including at least
three in a region near the chr4 peak that is predicted to encode multiple KRAB-zinc finger
proteins (unpublished observation). Differentially expressed genes of interest were also
found within other QTL regions include Vegfa; Notch4; Mllt4 (Afadin), a Ras-associated
adherens junction gene; and Ddr1, discoidin domain tyrosine kinase receptor, found in the
chr17 QTL region, plus a tumor suppressor gene, death-associated protein kinase, Dapk1,
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located within the chr13 QTL region and expressed in B6.Rag but not in NOD.Rag cells
(Fig. 3F).
Signaling and developmental differences between NOD.Rag and B6.Rag thymocytes
The enrichment of differentially expressed signal transduction pathway genes suggests that
inappropriate signaling might underlie the NOD.Rag checkpoint breakthrough. Thymocytes
from sex-matched 4–5 wk old pre-breakthrough NOD.Rag and B6.Rag mice were assayed
for differences in responses to the protein kinase C activator PMA, in short- and long-term
assays. Thymocytes from both strains used for these experiments were phenotypically
similar and >90% were DN3 stage cells (18). Phosphorylation of Erk1/2, mediators of the
Ras/MAPK pathway, was measured at by phospho-Erk1/2 (pErk) intracellular staining of
thymocytes from mice stimulated with PMA (Fig. 4A). NOD.Rag populations exhibited
cells with consistently lower levels of pErk than B6.Rag in response to PMA stimulation,
over all PMA concentrations tested, as shown by plotting MFI ratios between pairs of
matched cells (NOD:B6), over multiple experiments, which are almost uniformly below an
expected equal value of 1 (red line) (Fig. 4B). These results are in agreement with a recent
report showing differences in Erk1/2 phosphorylation between B6 and NOD TCR-
transgenic T cells (38).
PMA with calcium ionophore can mimic β-selection-promoting signals in vitro to drive
Rag-deficient thymocytes to generate DP cells in long-term cultures. Therefore, NOD.Rag
and B6.Rag thymocytes were also tested for developmental responses to these signals in co-
culture with OP9 stromal cells expressing Notch ligand, delta-like 1 (OP9-DL1). OP9-DL1
coculture supports T-cell development through the β-selection checkpoint in thymic
progenitors from WT B6 and NOD mice (17, 39), but not from Rag-deficient mice unless an
artificial TCR signal is delivered. Cells were treated with graded doses of PMA and calcium
ionophore and analyzed after 7 days. NOD.Rag cells (dashed lines) were more sensitive to
PMA than B6.Rag cells (solid lines) in this assay, as seen by the shift in dose response
curves for both total cell numbers (Fig. 4C, left), and the percentage of cells that had
progressed through the β-selection checkpoint, as measured by %CD4+ cells (including DP)
(Fig. 4C, right). These results demonstrate consistent differences between the two strains in
the responses of their thymocytes to a specific stimulus.
Breakthrough NOD.Rag DN cells upregulate Phase I stem/progenitor cell genes
NOD.Rag DP breakthrough cells only partially resemble post-β-selection cells. They
express surface CD4, CD8, and CD2 and initiate TCR-Cα and Bcl-XL transcription like
normal or induced DP cells, while also retaining characteristics of pre-β-selection DN cells
such as surface CD25, KIT, and IL7Rα, and Spib and Hes1 transcription (18). To determine
whether these were isolated cases or indicators of more general program derangement, the
transcriptome data were analyzed for the earliest breakthrough-specific gene changes by
comparing NOD.Rag cells (N7) with pre-breakthrough NOD.Rag (N4) and normal B6.Rag
(B4, B7) cells. Sorted N7 cells excluded breakthrough cells expressing surface CD4 but
included their precursors (Fig. 3A).
Very few genes exhibited a >3-fold difference between N7 and N4, and almost all were
higher in N7 (Fig. 5A). This finding is consistent with the emergence of a subpopulation of
abnormal cells, expressing novel genes; any down-regulated genes are likely to be masked
by the dominant presence of conventional DN3 cells. Fifty-two breakthrough-specific
differentially expressed genes were identified, including only those genes that distinguished
N7 from all other samples, N4, B4 and B7, by at least 3-fold (Fig. 5B, Supplemental Table
2). To determine if the emergent population more closely resembles pre- or post-β-selected
cells, we used our RNA-Seq data for WT B6 DN1 to DP cells (24) as a reference for the
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developmentally regulated expression of the N7-specific genes, and their patterns of
expression are shown in a heatmap in Fig. 5C. Strikingly, although the breakthrough
phenotype was originally identified by expression of post-β-selection markers CD2, CD4
and CD8, most of the genes preferentially expressed by N7 are normal Phase I genes. Of the
differentially expressed genes, 71% exhibited peak expression in Phase I (48% in DN1/ETP
and 23% in DN2a), 21% in Phase II (15% in DN2b and 6% in DN3), and only 8% in DP.
RNA-Seq tracks for some key Phase I genes, Lmo2, Hhex, Lyl1, Kit, and Mef2c (9), as well
as a post-β-selection gene, Cd2, are shown in Figure 5D. An additional Phase I gene, Dlk1
(Delta-like-1; Pref1), was expressed only in N7, as a previously unreported truncated splice
form (arrow). Dlk1 supports proliferation in hematopoietic progenitors, maintains cells in an
undifferentiated state, and is overexpressed in some leukemias (40).
The prominent expression of Phase I stem/progenitor genes suggests that the N7 emergent
population either failed to silence or reestablished the early T-cell program, which normally
occurs at the DN2 commitment checkpoint. At the same time, the emerging cells also appear
to bypass the β-selection checkpoint, as shown by expression of Cd2 and Cd5, which are
normally turned on in DN4 (www.immgen.org). While the assayed cells were selected to be
negative for surface CD4, Cd4 gene expression was detectably upregulated (1.9X higher in
N7 than in N4 cells). These results show that the emerging NOD.Rag breakthrough cells
have greatly disordered developmental programming and fail to passage or arrest properly at
the early T cell checkpoints (Fig. 1E).
NOD.Rag thymocyte numbers expand with age and in vitro
These features of the transcriptome analysis suggest a possible linkage between T cell
breakthrough and the high incidence of thymic lymphomas that appear in NOD.Rag mice
(18, 20, 21). NOD.Rag thymic cell numbers increase dramatically with age while B6.Rag
thymocyte cell numbers change very little or decline over time (Fig. 6A). Beginning at 20
wks, NOD.Rag mice exhibiting thymic lymphomas appeared, as previously reported (18,
21). In addition, when DN thymocytes from young NOD.Rag and B6.Rag mice were
cultured with Notch ligands and IL-7, both expanded but only NOD.Rag DN cells violated
the β-selection checkpoint and upregulated CD4 (Fig. 6B). Furthermore, NOD.Rag cells
isolated at 9–12 wks of age, after breakthrough but before lymphoma formation, expanded
continuously in cultures in the presence of Notch ligand and IL7. While sorted NOD.Rag
DP cells from 3 individuals expanded 6.7-fold ± 3.2 (SEM) over 5 days, and only generated
more DP cells, sorted CD25+ DN cells from the same mice expanded 3.1 ± 1.0 and
generated both DP cells and a small population of DN cells (Fig. 6C), suggesting that cells
within the DN population may be a source of illegitimate differentiation. These thymocytes
failed to survive when cultured in the absence of Notch ligands or IL-7 (data not shown),
indicating that they are committed to the T lineage.
Transcriptional regulatory relationship between NOD.Rag breakthrough thymocytes and
thymic lymphoma cells
If gene expression abnormalities in NOD.Rag breakthrough cells favored their
differentiation into lymphoma cells, then at least some of their aberrant features should be
preserved in the lymphomas that develop a few months after the breakthrough. To test this
prediction, we used real time QPCR on populations of NOD.Rag cells to track changes in
gene expression related to age and lymphoma status. We tested the persistence of
representative genes from various developmental stages, as well as a few genes that showed
differential expression between NOD.Rag and B6.Rag DN cells (Fig. 6D–G), using RNA
from the following sorted thymocyte populations: CD25+DN cells from 4–10 wk old
B6.Rag (arrested at the β-selection checkpoint, brown); CD25+DN cells from 4–6 wk old
NOD.Rag mice (arrested at the β-selection checkpoint, before overt breakthrough, dark
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green); DN, CD4+, and DP cells from post-breakthrough 10–16 wk old NOD.Rag mice
(light green); unsorted thymic lymphoma cells from >4 mo old NOD.Rag mice (pink); and
ETP, DN2a, DN2b, DN3a, and DP cells from WT NOD thymuses for comparison (blue).
NOD.Rag thymocytes obtained from all ages, including CD4+ and DP breakthrough cells
and thymic lymphomas, expressed critical T-cell genes, including Bcl11b, Tcf7, CD3e, and
Zap70 (Fig. 6D). Bcl11b expression in all NOD.Rag samples is particularly significant, as it
is critical for Phase I gene repression and T-cell differentiation past the DN2a stage (6, 7).
Bcl11b was reported to be a haploinsufficient tumor suppressor in human T-ALL (41, 42),
and expression of Bcl11b, as well as CD3e, was indeed lower by 2–3x in breakthrough and
lymphoma cells in comparison with B6.Rag and NOD WT DN3a/DP controls. A key TCR
signaling gene, Zap70, was consistently expressed at higher levels in NOD.Rag cells than in
B6.Rag cells, and Il7ra, a critical early T-cell cytokine receptor, was sustained at high levels
in almost all populations. Continuing expression of Il7ra in all breakthrough cell stages and
in thymic lymphoma cells supports the requirement for IL-7 for cell proliferation in early T
cells, and this pathway has been reported to be critical in human early T-ALL (43).
Notch signaling is required for early but not later stages of T-cell development (44) and
constitutive Notch activation is one of the most potent and common oncogenic factors in T-
ALL (45). Expression of Notch1, and target genes Dtx1, Hes1, Heyl, and Ptcra, was
sustained in all stages, including in lymphoma cells (Fig. 6E), implying sustained Notch
signaling.
Among Phase I genes (Fig. 6F), Kit expression was sustained at high levels in NOD.Rag
cells at all ages, and in lymphoma cells. Lmo2 was upregulated >100-fold between 4 and 6
wks in NOD.Rag cells, declined in breakthrough CD4+ and DP cells, but was still expressed
in all lymphoma cells. Hhex was also elevated in most NOD.Rag cells including all
lymphomas. Lyl1 and Sfpi1 levels varied between different NOD.Rag cell populations, but,
like Lmo2 and Hhex, both genes were still expressed in all thymic lymphoma cells at levels
higher than WT NOD DP cells. These Phase I genes are known proto-oncogenes and are
likely to be major contributors to the thymocyte expansion and lymphomas found in
NOD.Rag mice.
The lymphomas did not passively maintain gene expression patterns from DN and
breakthrough cells, as shown in Fig. 6G for representative differentially expressed genes,
each showing distinctive expression patterns. Of particular interest, the NOD-specific high-
level expression of Epha2 (in the chr4 QTL peak) began before breakthrough and was
maintained in all stages including all lymphomas. QPCR analysis also showed Epha2 to be
differentially expressed between WT NOD and B6 cells, at all DN stages, and in DP and
γδT cells (Supplemental Fig. 1A). Higher NOD.Rag cell expression of Mllt4 (Afadin, in
chr17 QTL peak) was also confirmed, but expression levels declined with age. Expression of
the tumor suppressor kinase, Dapk1 (chr13 QTL peak) was lower in NOD.Rag cells,
although some expression persisted in the lymphomas. WT NOD cells also showed a lower
expression of Dapk1 in all stages of development in comparison with B6 cells, especially in
the DN2a and DP stages where it is undetectable (Supplemental Fig. 1B). Expression of
Vegfa and Tnfrsf9 declined with age, however Vegfa was consistently expressed in the
lymphomas while Tnfrsf9 was variable. Overall, the lymphoma cells maintained many of
the unique gene expression patterns found in NOD.Rag N7 cells, especially expression of
Phase I proto-oncogenes, suggesting that origins of the transformed cells may lie in the early
breakthrough cells which fail to shut off the genes that sustain the pleuripotency and
proliferation of progenitor T cells (Fig. 1E).
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Discussion
Thymic lymphomas generated in mice with an NOD genetic background preserve many
gene expression features of the early breakthrough cells, which themselves emerge as the
result of an earlier dysfunction. From the transcriptome analysis, the dominant feature of
breakthrough cells emerging spontaneously in the NOD.Rag thymus is the collapse of two
regulatory boundaries: one that normally distinguishes pre-commitment ETP and DN2a
stage cells from committed DN3 cells, the other operating at the β-selection checkpoint that
requires a TCR signal for DN3 to DP progression (Fig. 1E). The breakthrough cells and the
later-arising lymphoma cells share a highly abnormal co-expression of legacy progenitor cell
genes, including proto-oncogenes, normally restricted to uncommitted ETP and DN2a cells,
along with T cell genes characteristic of later stage cells, before and after TCR-dependent β-
selection. Unlike normal Rag-deficient cells, breakthrough thymocytes undergo long-term
expansion and aberrant differentiation in vitro, and thymic cell numbers increase with age in
vivo, even before thymic lymphomas appear. Thus, the breakthrough cells may include a
population of pre-leukemic cells, which can provide cellular targets of oncogenic
transformation.
One striking feature of the T cell commitment checkpoint in the DN2 stage is the brief
period of overlap in Phase I and T cell identity genes during the transition from dominant
expression to silencing of legacy stem cell genes after the onset of expression of T cell
specific genes (5, 9). The most notable feature of our current transcriptome and QPCR data
is the apparent failure to terminate the Phase I ETP-DN2 progenitor/stem cell program in
early breakthrough cells despite upregulation of T cell specific genes including Bcl11b,
which is involved in their silencing (6), making the breakthrough cells appear to be retained
in a DN2-like state. Expression of genes such as Cd2, Cd5, and Cd4 indicate a bypass of the
later β-selection checkpoint as well, possibly due to an aberrant pre-TCR-like signal. It is
also possible that failure of the first checkpoint might prevent the normal establishment of
the second checkpoint, making the DN2 stage the critical point of breakthough vulnerability.
Aberrant signal transduction at one or both checkpoints as a promoter of breakthrough is
suggested by the transcriptome data showing a marked overrepresentation of signaling
genes, especially actin-binding proteins and tyrosine kinases, among differentially expressed
genes between NOD.Rag and B6.Rag thymocytes. Actin/cytoskeletal and signal
transduction pathways are interrelated in TCR signaling (36), and alterations in expression
of key genes may trigger inappropriate signaling at the checkpoints. Evidence that activated
NOD CD4+ cells exhibit a higher overall level of phospho-tyrosine than B6 cells (46)
supports a potential role for at least some of the 11 differentially overexpressed tyrosine
kinases in NOD.Rag cells and we show in vitro evidence for subtle but consistent strain-
specific differences in responses to PMA between cells from the two strains. Furthermore,
consistent differences in Erk1/2 phosphorylation have also been reported for immature and
mature NOD and B6 TCR-transgenic T cells (38).
The NOD.Rag mixed gene expression signature of early breakthrough T cells and thymic
lymphoma cells that emerge at high frequency after 4–5 mo, is shared with certain human
acute T cell lymphocytic leukemias (T-ALL), especially of the early LYL1-LMO2 T-ALL
subgroup (47), as well as the recently described ETP-ALL, whose gene signatures share
features with normal ETP and myeloid cells (48). ETP-ALL also shares similarities with
both T cell and myeloid stem cells, and mutations in cytokine (Flt3 and IL7R) and Ras
signaling pathways are prominent (43). In common with ETP-ALL, NOD.Rag breakthrough
cells express genes indicative of their early T cell programming, e.g., Bcl11b, Ptcra and Il7r,
in addition to stem/progenitor genes such as Lmo2, Hhex, Lyl1, Kit, Sfpi1, which also likely
contribute to the myeloid potential of WT NOD and B6 ETP/DN2a cells (5). The prominent
overexpression of Lmo2 in the NOD.Rag breakthrough cells is noteworthy as DN cells
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overexpressing transgenic Lmo2 develop into self-renewing thymocytes, with striking gene
expression similarities to NOD.Rag breakthrough cells, followed by T-ALL eight months
later (49). The NOD.Rag breakthrough and thymic lymphoma development may be only
partially attributable to the enhanced expression of Lmo2, as thymic tumors appear much
more rapidly in NOD.Rag mice, beginning two months after breakthrough cells first appear,
possibly due to the elevated expression of tyrosine kinases, which are commonly oncogenic
(37).
Genes within the identified QTL regions control propensity for breakthrough in the NOD
genetic background and they mapped to known autoimmune diabetes susceptibility regions.
The strong chr4 QTL peak in the Idd9/11 region (14) clearly includes at least one recessive
NOD allele needed to promote efficient breakthrough, as shown by the reduced
breakthrough in congenic NOD.B10Idd9Rag mice. Possible breakthrough-enhancing QTL
regions were also detected in the Idd16/23/1/24 region on chr17, Idd14 on chr13, and Idd4
on chr11. Although all of the QTL regions remain too large to determine if any of the same
genes control both autoimmunity and the early T-cell breakthrough, the close mapping of
the two different T-cell related phenotypes is highly suggestive and requires further analysis
to pinpoint source genes. The B10 Idd9 congenic region, which protects against the
breakthrough trait, is reported to protect NOD mice against Type 1 diabetes after
lymphocytic infiltration in the pancreas, suggesting control over the balance between
pathogenic and protective T-cell responses (14). If the differentially expressed genes found
within the QTL regions are also used in establishing self-tolerance, then the autoimmunity
promoting T cell defects may be traceable to the earliest common T cell progenitors, even
before TCR rearrangement occurs.
To date, animal models of T-ALL have typically depended on artificial gene expression
alterations such as ablation of tumor suppressor genes or transgenic overexpression of
oncogenes (50). The results reported here suggest that the NOD.Rag mouse may be a useful
unmanipulated model for studying oncogenic progression from a pre-leukemic state, which
arises spontaneously and predictably from defects in early T cell checkpoint control.
Moreover, our genetic analysis suggests a potential linkage to autoimmune diabetes in WT
NOD mice, possibly related to an intrinsic defect in thymic αβT-cell development, which
also arises from ETP-DN2 stages (17). Human epidemiological studies have linked T-ALL
and autoimmune Type 1 diabetes, both of which are predominantly pediatric diseases (51,
52). Furthermore, genes and molecular pathways involved in lymphocyte immune
checkpoints and tumor suppression overlap, and the consequences of loss of checkpoint
control, which sets thresholds for appropriate proliferation and survival, can be key in both
autoimmunity and in lymphoid cancers (53). Thus, our results could extend alterations in T
cell selection and functions back to the earliest stages of their development and raise the
possibility that genes involved in an early commitment checkpoint breakthrough may
contribute to defects in lymphocyte homeostasis and both T cell leukemia and autoimmune
disease.
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Figure 1.
Genome-wide QTL analysis of the NOD.Rag early T-cell breakthrough trait shows mapping
to known diabetes susceptibility regions. (A) Flow cytometric data showing representative
%CD4+ vs. %CD8+ and %Kit+ vs. %CD25+ phenotyping plots for thymocytes from control
parental B6.Rag, NOD.Rag, and F1.Rag, as well as 2-(NOD X B6)F2.Rag cross mice at 14
wks of age. (B) Scatterplot showing the correlation between the two measured thymocyte
phenotypic traits: %CD4+ and %Kit+ cells. (C) Genome-wide QTL scan for %CD4+ and
%Kit+ thymocytes, using the combined N2 plus F2 crosses. LOD scores are plotted for
%CD4+ cells (black) and %Kit+ cells (gray) for all 19 autosomal chromosomes. Black line
indicates a LOD score of 3. (D) Expanded plots of LOD scores for the chromosomes with
the highest peaks in the combined cross, chr4 and chr17, for the two phenotypes, %CD4+
and %Kit+ thymocytes. Approximate regions of known diabetes susceptibility Idd loci are
also noted. (E) Diagram of key early T-cell developmental stages (based on (9)) and possible
pathways (dashed and solid arrows) leading to pro-T-cell checkpoint breakthrough and T-
cell lymphocytic leukemia (T-ALL) in NOD.Rag mice.
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Figure 2.
NOD.B10Idd9Rag congenic mouse strain analysis of the chr4 Idd9 QTL peak region. (A)
Diagram of the chr4 congenic region from NOD.B10Idd9 (L. Wicker, Cambridge, UK),
which was crossed onto NOD.Rag congenic mice. Indicated are the genomic regions derived
from B10Idd9 (black) and NOD (white), and the recombination region (gray), as well as the
Mappair markers used in the congenic cross and the QTL peak (arrow). Approximate
locations for Idd9.1, 9.2 and 9.3 are shown (from T1Dbase.org). (B) Flow cytometric
analysis of B6.Rag, NOD.Rag and four NOD.B10Idd9Rag congenic mice at 12 weeks of age.
(C) Summary of %CD4, %DP, and %Kit+ cells, for individual NOD.B10Idd9Rag
(NOD.chr4Rag) congenic mice in comparison with parental B6.Rag, NOD.Rag, F1.Rag
mice, all at 12–16 wks old. p-values are from t-tests comparing data from NOD.Rag and
NOD.B10Idd9Rag mice.
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Figure 3.
RNA-Seq transcriptome analysis comparing CD25+DN thymocytes from B6.Rag and
NOD.Rag mice. (A) Gates used for sorting phenotypically similar CD4−CD25+ cells for
RNA purification: B6.Rag at 4 and 7 wk (B4, B7) and NOD.Rag at 4 and 7 wk (N4, N7).
(B) Difference versus mean of log2 expression of N4/N7 and B4/B7, including 11,098 genes
expressed at >32 reads in at least one sample. Horizontal gray lines show 3- and 4-fold
differences. Genes differing by >3-fold are shown in dark circles, <3-fold by gray circles.
(C) Heat map for hierarchical clustering of 412 genes differing by >3X between N(4 and 7)
vs. B(4 and 7). Data are shown as log2(RPKM/GeoMean). (D) Hierarchical cluster heat
maps showing the normal (WT B6) developmentally regulated expression (log2(RPKM/
GeoMean)) of differentially expressed genes that are higher (top) and lower (bottom) in N(4
and 7) compared with B(4 and 7) using our previously published data (24). (E–F) RNA-Seq
tracks showing sequence read histograms for expressed genes of interest in QTL regions
from B6.Rag and NOD.Rag CD25+ DN cells at 4 and 7 wks of age. Gene tracks are shown
using the UCSC browser and the data are mapped onto the mouse genome build NCBI37/
mm9. (E) Genes located in the chr4 major QTL region, including differentially expressed
genes, Epha2, Padi3, Tnfrsf9 (4–1BB), Ctnnbip1 (Icat), a differentially spliced gene, Hdac1
(differentially spliced exons indicated with arrows), and Lck, a non-differentially expressed
gene for reference. (F) Differentially expressed genes in the chr17 QTL region, including
Vegfa, Notch4, Mllt4 (Afadin), and Ddr1, and in the chr13 QTL region, Dapk1.
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Figure 4.
NOD.Rag and B6.Rag thymocytes exhibit differential responses to PMA stimulation. (A)
Representative flow cytometric histogram showing intracellular Erk1/2 phosphorylation
(pErk1/2) in freshly isolated thymocytes (>90% DN3 cells) from pre-breakthrough
NOD.Rag and B6.Rag mice treated for 2 min. with PMA. (B) Summary plot of the NOD:B6
ratios of pErk1/2 (using geometric mean fluorescence intensity (MFI) from intracellular
staining) for thymocytes from age-and sex-matched NOD.Rag and B6.Rag mice treated with
1 to 25 ng/l PMA. The MFI was consistently lower for NOD.Rag cells than for B6.Rag cells
as shown by ratios lower than 1 (equal expression, indicated with a red line). Data included
are combined from 5 independent experiments. (C) Responses of thymocytes from 6 wk old
NOD.Rag (dashed lines) and B6.Rag (solid lines), placed in co-culture with OP9-DL1 cells
and stimulated with graded doses of PMA, and calcium ionophore A23187 (CI: doses of 0,
22, 43, and 87 nM as indicated), and assayed at day 7 for cell number (left graph) and
%CD4+ cells (right graph). Representative of 3 independent experiments.
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Figure 5.
RNA-Seq transcriptome analysis of NOD.Rag breakthrough cells. (A) Difference versus
mean of log2 expression of NOD.Rag 7 wk (N7, at breakthrough) vs. 4 wk (N4, pre-
breakthrough). Horizontal gray lines show 3- and 4-fold differences. Genes differing by >3-
fold are shown in dark circles, <3-fold by gray circles. (B) Heat map for hierarchical
clustering of 52 genes differing by >3X between N7 vs. all other samples. Data are shown as
log2(reads per kilobase per million reads (RPKM)/Geometric mean (GeoMean)). (C)
Hierarchical cluster heat map showing the WT B6 expression profile (log2(RPKM/
GeoMean)) of 52 genes differentially expressed between N7 and other samples using data
from ETP to DP developmental stages (24). (D) RNA-Seq gene tracks from B6.Rag and
NOD.Rag CD25+ DN cells at 4 and 7 wks of age showing a selection of genes of interest
expressed >3-fold higher in N7 in comparison to N4, B4 and B7, including Phase I genes,
Lmo2, Hhex, Lyl1 Kit, and Mef2c, post-β-selection gene, Cd2, and a differentially
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expressed and spliced Notch-related gene, Dlk1 (lack of expression of 3′ exon(s) is
indicated with an arrow).
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Figure 6.
Changes in thymocyte cell number, in vitro potential, and gene expression with age and
lymphoma. (A) Plot of thymocyte cell numbers with age showing the increase in cell
numbers with age in NOD.Rag but not B6.Rag mice. (B) DN cells from 6 wk old pre-
breakthrough NOD.Rag mice cultured with OP9-DL1 stroma plus IL-7 exhibit upregulation
of CD4 while B6.Rag cells do not express CD4. (C) Sorted CD25+ DN and DP cells from a
12 wk old NOD.Rag mouse proliferate and differentiate when cultured on OP9-DL4 stroma
supplemented with 5 ng/ml IL-7 for 3 and 16 days before FACS analysis for expression of
CD4 and CD8. Data are representative of 2 experiments. (D–G) Real time QPCR expression
of some developmentally regulated genes in sorted B6.Rag CD25+DN cells, from 4, 6, and
10 wks of age (brown bars), sorted NOD.Rag pre-lymphoma CD25+DN, CD4+ and DP
cells, from 4, 6, 10, 13, and 16 wks of age (green bars), unsorted cells from 5 independent
NOD.Rag lymphomas (pink bars), and representative WT NOD DN1/ETP, DN2a, DN2b,
DN3a, and DP cells for reference (blue bars). Relative gene expression levels are shown for
representatives of (D) key T-cell genes, (E) Notch and target genes, (F) Phase I (ETP/DN2a)
genes, and (G) differentially expressed genes from the transcriptome analysis.
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Table 2
Gene ontology analysis on >3-fold differentially expressed genes between NOD.Rag and B6.Rag CD25+ DN
cells showing major enriched categories of genes.
GOTERM CATEGORY GENES1 FOLD ENRICHMENT p-value Benjamini
MHC protein complex H2-K1, H2-Q2, H2-M6-PS, H2-Q10, C920025E04rik,
H2- OA, H2-BL, H2-Q1, H2-T10, H2-AB1, H2-Q7,
H2-T3 (all chr17)2
9.8 6.5E-07 1.6E-04
Actin binding Lima1, Ccdc88a, Mybpc2, Tln2, Inppl1, Myo7a, Evl,
Spire2, Tpm3, Coro2b, Fmn2, Syne2, Mtap1a, Capg,
Tmod4, Eps8l1, Mylk, Myh10 (chr11)
3.5 1.8E-05 7.9E-03
Protein tyrosine kinase
activity
Tyro3, Ddr1 (chr17), Fgfr1, Ptk2, Ltk, Ptpn3, Ptk2b,
Hck, Txk, Ephb4, Epha2 (chr4)
3.7 7.7E-04 1.1E-01
Adherens junction Ptk2, Lima1, Itga6, Ptk2b, Tln2, Lmo7, Evl, Mllt4
(chr17), Arhgap26
4.3 1.1E-03 6.8E-02
Protein kinase activity Tyro3, Fgfr1, Alpk1, Ltk, Ptpn3, Hck, Ulk4, Ephb4,
Epha2 (chr4), Dapk1 (chr13), Rps6kl1, Ddr1 (chr17),
Ptk2, Ptk2b, Camk1, Stk39, Camk2B, Txk, Grk5,
Camk2a, Mylk
2.0 4.3E-03 1.9E-01
Calmodulin binding Adcy1, Myo7a, Camk1, Camk2b, Camk2a, Mylk,
Myh10 (chr11), Dapk1 (chr13)
3.9 4.5E-03 1.8E-01
1Genes expressed at higher amounts in NOD.Rag cells are indicated in bold
2Genes located within a mapped QTL region in this study are noted (chr)
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